Table 2 Influence of characteristics on the biologic therapy withdrawal decision. This table shows the influence of patient-, disease- and treatment-characteristics on their influence on the decision to withdraw biologic therapy (column 2–4) and total duration of treatment in clinically inactive disease (column 5–7). The first column lists the independent variables in the model. The dependent variable is the decision to postpone withdrawal of biologic therapy. The second column presents the odds ratio that indicates the impact of each characteristic on a decision to postpone withdrawal of biologic therapy with confidence interval and significance level. Reference category for each characteristic is the most positive outcome, e.g. no history of uveitis. Time in clinically inactive disease (CID) is included as a covariate. This is the minimal time a pediatric rheumatologist would treat a child with non-systemic JIA with the most positive profile. Reference category for Time in CID is 12 months. The fifth column indicates the influence of each of the characteristics on the total treatment duration, in months after clinical remission is achieved, with confidence interval and significance level
From: Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?
Withdrawal of biologic therapy in children with clinically inactive non-systemic JIA | ||||||
|---|---|---|---|---|---|---|
Predictors | Odds Ratios | CI | p | Estimates | CI | p |
(Intercept) | 0.19 | 0.07 – 0.43 | < 0.001 | 16.56 | 11.40 – 21.71 | < 0.001 |
Time in CID [6 months] | 0.54 | 0.24 – 1.26 | 0.144 | -17.48 | -22.45 – -12.51 | < 0.001 |
Time in CID [9 months] | 0.24 | 0.10 – 0.56 | 0.001 | -15.42 | -21.00 – -9.84 | < 0.001 |
Time in CID [15 months] | 0.98 | 0.31 – 3.73 | 0.971 | 12.11 | 5.27 – 18.96 | 0.001 |
Time in CID [18 months] | 0.59 | 0.24 – 1.57 | 0.268 | 6.13 | 0.43 – 11.83 | 0.035 |
Time in CID [21 months] | 0.16 | 0.08 – 0.30 | < 0.001 | -0.11 | -4.46 – 4.25 | 0.962 |
Response time [The child was in remission at 12 months on the current biologic] | 1.74 | 0.96 – 3.18 | 0.067 | 0.15 | -2.97 – 3.26 | 0.927 |
RF [The child is RF Positive] | 1.77 | 1.01 – 3.12 | 0.046 | 7.81 | 4.70 – 10.92 | < 0.001 |
Flares [History of flares in the previous treatment period] | 1.50 | 0.81 – 2.94 | 0.207 | 1.06 | -2.74 – 4.87 | 0.583 |
Flares [Flare in the current treatment period] | 3.90 | 1.84 – 9.18 | 0.001 | 2.56 | -1.25 – 6.38 | 0.188 |
Joint [Joint damage in the current treatment period] | 2.39 | 1.34 – 4.47 | 0.004 | 3.27 | 0.16 – 6.38 | 0.040 |
Uveitis [Uveitis in the current treatment period, which is in remission] | 3.86 | 1.91 – 8.33 | < 0.001 | 3.29 | -0.53 – 7.12 | 0.091 |
Uveitis [History of uveitis in the previous treatment period] | 2.55 | 1.27 – 5.47 | 0.011 | 1.15 | -2.66 – 4.97 | 0.553 |
Spine [Spine involvement in the current treatment period] | 2.12 | 1.21 – 3.75 | 0.009 | 0.67 | -2.44 – 3.78 | 0.673 |
TMJ [TMJ involvement in the current treatment period] | 1.43 | 0.77 – 2.63 | 0.246 | 3.11 | -0.01 – 6.22 | 0.051 |
Failure [Failure of a biologic in the current treatment period] | 2.98 | 1.41 – 6.80 | 0.006 | 2.72 | -1.09 – 6.53 | 0.162 |
Failure [Treatment failure with a different biologic in the previous treatment period] | 2.32 | 1.21 – 4.54 | 0.012 | 4.36 | 0.54 – 8.17 | 0.025 |
Preference [Child and parents prefer to continue the biologic] | 6.34 | 3.51 – 12.19 | < 0.001 | 6.65 | 3.53 – 9.76 | < 0.001 |
Log(scale) | 2.88 | 2.82 – 2.95 | < 0.001 | |||
Observations | 528 | 528 | ||||
R2 Tjur | 0.336 | 0.242 | ||||